|
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation’s current portfolio consists of small molecule drugs in clinical development to treat three large, unmet medical needs – Alzheimer’s disease, Huntington’s disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs.
Recent Releases
Jul 17, 2008
Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease
Jul 7, 2008
Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease
more »
|
 Briefcase
 Download Library
 Email Alerts
 RSS News Feeds
For Investors
investors@medivation.com
For Media
media@medivation.com
Transfer Agent
American Stock Transfer
and Trust Company
59 Maiden Lane
New York, NY 10038
(800) 937-5449
www.amstock.com
|
